Physician profile
Charles A Gropper
NPI 1659332864
$26,534.25
in general payments reported to CMS, 2019-2025
25 companies · $1,853 in 2025
The $1,853 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,568 · 2020: $98.80 · 2021: $2,892 · 2022: $695 · 2023: $11K · 2024: $2,070 · 2025: $1,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $4,979 · Education: $80.45 · Travel and Lodging: $69.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,151.67 |
| Food and Beverage | $4,978.81 |
| Education | $80.45 |
| Travel and Lodging | $69.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $10,463.74 | 2023-2025 | Bimzelx |
| Pfizer INC. | $8,465.12 | 2019-2022 | |
| Abbvie INC. | $2,120.68 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $655.16 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $570.81 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $545.21 | 2019-2024 | |
| Incyte Corporation | $538.05 | 2022-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $506.97 | 2022-2025 | Nemluvio, Aklief |
| Takeda Pharmaceuticals U.S.A., INC. | $416.67 | 2024 | |
| Genzyme Corporation | $416.39 | 2021-2023 | |
| Dermavant Sciences, INC. | $388.12 | 2022-2024 | Vtama |
| Lilly USA, LLC | $183.13 | 2019-2024 | Olumiant |
| Blueprint Medicines Corporation | $182.70 | 2025 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $180.37 | 2022-2023 | Sotyktu |
| Regeneron Pharmaceuticals, INC. | $143.17 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $143.11 | 2020-2025 | Otezla |
| Dermira, INC. | $132.12 | 2019 | |
| Botanix Sb INC | $126.39 | 2025 | Sofdra |
| Almirall LLC | $118.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $99.60 | 2024 | Saphnelo |
| Sanofi-Aventis U.S. LLC | $49.48 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.98 | 2019 | |
| Leo Pharma INC. | $23.05 | 2022 | |
| Epi Health, LLC | $18.29 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Gropper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.